The comparison of the efficacy among three different nimorazole regimens in the treatment of bacterial vaginosis.
The efficacy of 3 different nimorazole regimens in treating bacterial vaginosis in women was evaluated. The regimens consisted of: Nimorazole 2 g single dose (Group I), 1 g per day for 3 days (Group II), and 1 g per day for 7 days (Group III) orally. In a simple randomized trial of 90 cases (30 cases in each group) with demonstrated clinical bacterial vaginosis on the presence of 3 of 5 of the following signs: (1) Characteristic thin homogenous discharge; (2) vaginal pH greater than 4.5; (3) release of a fishy amine odor from vaginal fluid mixed with 10% KOH; (4) presence of clue cells (usually representing at least 20% of vaginal epithelial cells); and (5) vaginal fluid contains few or no lactobacilli. Cure rates for bacterial vaginosis by nimorazole were 70.0% (21/30), 83.3% (25/30), and 90.0% (27/30) in Group I, II, and III, respectively. Thus nimorazole is another effective drug for the treatment of bacterial vaginosis.